Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2008-10-07
2010-11-23
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S251000
Reexamination Certificate
active
07838489
ABSTRACT:
Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.
REFERENCES:
patent: 4695459 (1987-09-01), Steinman et al.
patent: 5096906 (1992-03-01), Mandell et al.
patent: 5204329 (1993-04-01), Ackerman et al.
patent: 5260422 (1993-11-01), Clark et al.
patent: 5298396 (1994-03-01), Kotzin et al.
patent: 5317019 (1994-05-01), Bender et al.
patent: 5468481 (1995-11-01), Sharma et al.
patent: 5502066 (1996-03-01), Heinemann et al.
patent: 5580873 (1996-12-01), Bianco et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5672347 (1997-09-01), Aggarwal et al.
patent: 5698195 (1997-12-01), Le et al.
patent: 5741488 (1998-04-01), Feldmann et al.
patent: 5795967 (1998-08-01), Aggarwal et al.
patent: 5919452 (1999-07-01), Le et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5994510 (1999-11-01), Adair et al.
patent: 6015557 (2000-01-01), Tobinick et al.
patent: 6177077 (2001-01-01), Tobinick
patent: 6190691 (2001-02-01), Mak
patent: 6270766 (2001-08-01), Feldman et al.
patent: 6770279 (2004-08-01), Feldmann et al.
patent: 2002/0010180 (2002-01-01), Feldmann et al.
patent: 2002/0068057 (2002-06-01), Feldmann et al.
patent: 2002/0136723 (2002-09-01), Feldmann et al.
patent: 2004/0228863 (2004-11-01), Feldmann et al.
patent: 2006/0099212 (2006-05-01), Feldmann et al.
patent: A-58976/90 (1991-02-01), None
patent: 92/17649 (1992-03-01), None
patent: 93/51522 (1993-10-01), None
patent: 1997/021229 (1997-02-01), None
patent: 2003/264629 (2003-12-01), None
patent: 2021369 (1991-01-01), None
patent: 0 240 344 (1987-10-01), None
patent: 0 288 088 (1988-10-01), None
patent: 40 06 269 (1991-08-01), None
patent: 0 914 157 (2005-10-01), None
patent: 1 941 904 (2008-07-01), None
patent: 2 246 569 (1992-02-01), None
patent: 2246569 (1992-02-01), None
patent: 0 663 836 (1997-07-01), None
patent: WO 89/08460 (1989-09-01), None
patent: WO 90/15152 (1990-12-01), None
patent: WO 90/15152 (1990-12-01), None
patent: WO 91/00092 (1991-01-01), None
patent: WO 91/02078 (1991-02-01), None
patent: WO 91/10722 (1991-07-01), None
patent: WO 92/07076 (1992-04-01), None
patent: WO 92/07585 (1992-05-01), None
patent: WO 92/08474 (1992-05-01), None
patent: WO 92/11383 (1992-07-01), None
patent: WO 92/16553 (1992-09-01), None
patent: WO 93/07863 (1993-04-01), None
patent: WO 94/06476 (1994-03-01), None
patent: WO 94/08619 (1994-04-01), None
patent: WO 94/08619 (1994-04-01), None
patent: WO 95/03827 (1995-02-01), None
patent: WO 95/09652 (1995-04-01), None
patent: WO 96/33204 (1996-10-01), None
patent: WO 98/24463 (1998-06-01), None
patent: WO 98/05357 (1998-12-01), None
patent: WO 00/50079 (2000-08-01), None
Preliminary Opinion issued Jul. 13, 2009 by the Opposition Division of the European Patent Office in connection with Oppositions filed against counterpart European Patent Application No. 97933799.5, filed Aug. 1, 1997.
Response to Patentee's May 18, 2007 submission including an Amendment to the Consolidated List of References Submitted by the Patentee with Letter of May 18, 2007, submitted Jan. 28, 2008 by Opponent, Amgen, in connection with the Oppositions against counterpart European Patent No. EP 0 914 157, granted Oct. 5, 2005.
Response to Opponent Amgen's Jan. 28, 2008 submission submitted Sep. 29, 2008 in connection with the Oppositions against counterpart European Patent No. EP 0 914 157, granted Oct. 5, 2005.
Response to Patentee's Sep. 29, 2008 submission submitted Jan. 26, 2009 by Opponent, Amgen, in connection with the Oppositions against counterpart European Patent No. EP 0 914 157, granted Oct. 5, 2005.
Breedveld, F.C. et al., “New Perspectives on Treating Rheumatoid Arthritis,”New England Journal of Medicine, 1995, 333(3), 183-184.
Bologna, C. et al., “Association of Methotrexate (MTX) and Steroids in the Treatment of Rheumatoid Arthritis (RA) Patients,”Arthritis&Rheumatism, 1995, 38, S366, Abstract #1280.
O'Dell, J. et al., “Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxycholoroquine, or a combination of all three medications,”New England Journal of Medicine, 1996, 334(20): 1287-1291.
Canadian Office Action, issued Nov. 3, 2009, in connection with counterpart Canadian Patent Application No. 2,261,630, filed Aug. 1, 1997.
Dec. 3, 2009 Response to the Jul. 24, 2009 Official Communication issued by the European Patent Office in connection with counterpart European Divisional Patent Application No. 5 076 131, filed Aug. 1, 1997, including a Main Request and Auxiliary Request.
Schröder, O. et al., (2004) “Infliximab and Methotrexate in fistulising Crohn's disease resistant or intolerant to azathioprine,”Aliment Pharmacol. Ther., 19: 295-301.
European Medicines Agency (EMEA): Remicade, European Public Assessment Report (EPAR) Scientific Discussion, Jun. 1, 2006.
Katsicas M., & Russo R., (2009) “Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab,”Clin. Rheumatology, 28: 985-988.
European Medicines Agency (EMEA) : Post-Authorisation Summary of Positive Opinion for Humira, Jul. 24, 2008.
Perez-Guijo, V. et al., (2007) “Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis,”Revue du Rhumatisme, 74: 470-474.
Communication forwarding Nov. 23, 2009 Observations by Opponent, Abbott Laboratories, issued Dec. 4, 2009 in connection with the Oppositions against counterpart European Patent No. EP 0 914 157, granted Oct. 5, 2005, including the Nov. 23, 2009 Observations.
Office Action issued Dec. 24, 2009 in connection with U.S. Appl. No. 11/225,631, filed Sep. 12, 2005.
Jan. 22, 2010 Response to Jul. 13, 2009 Communication by Opposition Division in connection with the Oppositions to counterpart European Patent No. EP 0 914 157, granted Oct. 5, 2005.
Harrison's Principles of Internal Medicine, Fourteenth Edition, 1998, Ed: Fauci, A.S. et al., McGraw-Hill, pp. 1753 and 1760.
Scheidereit et al., In “Protein Phosphorylation in Cell Growth Regulation” Ed Michael J. Clemens, 1996, Harwood Academic Publishers GmbH, Netherlands., pp. 184-186.
Communication forwarding Jan. 25, 2010 Observations by Opponent, Wyeth, issued Feb. 4, 2010, in connection with the Oppositions against counterpart European Patent No. EP 0 914 157, granted Oct. 5, 2005, including the Jan. 25, 2010 Observations.
Lara-Ochoa, F., et al., (1996) “Antibody-Antigen Recognition: A Canonical Structure Paradigm”J. Mol Evol.43:678-684.
Fundamental Immunology, Sixth Edition, 2005, Paul, W., et al., Lippincott Williams & Wilkins and Wolters Kluwer, p. 136.
Immuno Biology, The Immune System in Health and Disease, 2001, Janeway, C., et al., Garland Publishing.
Communication pursuant to Article 94 (3) EPC issued Apr. 6, 2010 by the European Patent Office in connection with counterpart European Divisional Patent Application No. 08 005 013, filed Aug. 1, 1997.
Office Action issued Nov. 3, 2009 by the Canadian Intellectual Property Office in connection with counterpart Canadian Patent Application No. 2,261,630.
May 3, 2010 Response to the Nov. 3, 2009 Office Action issued by the Canadian Intellectual Property Office in connection with counterpart Canadian Patent Application No. 2,261,630.
Moreland, et al.,Arthritis&Rheumatism, vol. 38, No. 11, Nov. 1995, Abstract.
Ernst Schering Prize Press Release dated Mar. 24, 2010 announcing Professors Ravinder Maini and Marc Feldmann as recipients of the 2010 Ernst Schering Prize.
May 7, 2010 Response to the Dec. 24, 2009 Office Action issued by the United States Patent and Trademark Office in connection with U.S. Appl. No. 11/225,631.
U.S. Appl. No. 07/958,248, filed Oct. 8, 1992, Marc Feldmann et al.
U.S. Appl. No. 08/607,419, filed Feb. 28, 1
Feldmann Marc
Maini Ravinder Nath
Cooper & Dunham LLP
Gambel Phillip
The Mathilda and Terence Kennedy Institute of Rheumatology Trust
White John P.
LandOfFree
Methods of treating rheumatoid arthritis with p75 TNF-alpha... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating rheumatoid arthritis with p75 TNF-alpha..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating rheumatoid arthritis with p75 TNF-alpha... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4159141